Future oncology (London, England) · 2026
Real-world comparison of chemoimmunotherapy and chemotherapy alone in elderly patients (≥75 years) with extensive-stage small cell lung Cancer.
СтатьяСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dong Xue, Chen Wenjie, Li Ruyue, Yao Xiujing, Li Yintao
Аннотация
INTRODUCTION: Given the underrepresentation of adults aged ≥75 years with extensive-stage small-cell lung cancer (ES-SCLC) in clinical trials, we compared first-line chemoimmunotherapy versus chemotherapy in this population.
METHODS: This retrospective study enrolled 88 patients aged ≥75 years with ES-SCLC treated with either chemotherapy alone (n = 42) or chemoimmunotherapy (n = 46). The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS) and safety. Multivariable Cox regression and stabilized inverse probability of treatment weighting (IPTW) analyses were performed to reduce confounding.
RESULTS: Median OS and PFS were 14.3 (95% CI: 11.6-22.5) and 6.6 in the chemotherapy group and 16.9 (95% CI: 12.7-NA) and 7.6 months in the chemoimmunotherapy group, respectively (HR: 0.90, 95% CI: 0.51-1.58, p = 0.71; HR: 0.75, 95% CI: 0.43-1.29, p = 0.30, respectively). Multivariate analysis identified smoking status as an independent predictor of OS (HR: 2.10, 95% CI: 1.01-4.38, p = 0.048).
CONCLUSION: Among patients aged ≥75 years with ES-SCLC, chemoimmunotherapy was associated with numerically longer OS compared with chemotherapy alone, although this difference did not reach statistical significance.
METHODS: This retrospective study enrolled 88 patients aged ≥75 years with ES-SCLC treated with either chemotherapy alone (n = 42) or chemoimmunotherapy (n = 46). The primary endpoint was overall survival (OS). Secondary endpoints included progression-free survival (PFS) and safety. Multivariable Cox regression and stabilized inverse probability of treatment weighting (IPTW) analyses were performed to reduce confounding.
RESULTS: Median OS and PFS were 14.3 (95% CI: 11.6-22.5) and 6.6 in the chemotherapy group and 16.9 (95% CI: 12.7-NA) and 7.6 months in the chemoimmunotherapy group, respectively (HR: 0.90, 95% CI: 0.51-1.58, p = 0.71; HR: 0.75, 95% CI: 0.43-1.29, p = 0.30, respectively). Multivariate analysis identified smoking status as an independent predictor of OS (HR: 2.10, 95% CI: 1.01-4.38, p = 0.048).
CONCLUSION: Among patients aged ≥75 years with ES-SCLC, chemoimmunotherapy was associated with numerically longer OS compared with chemotherapy alone, although this difference did not reach statistical significance.